TG Therapeutics (NASDAQ: TGTX) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare TG Therapeutics to related businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations.


This table compares TG Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TG Therapeutics -68,806.59% -154.02% -117.88%
TG Therapeutics Competitors -3,550.10% -115.58% -42.28%

Analyst Recommendations

This is a summary of current ratings and price targets for TG Therapeutics and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics 0 0 9 0 3.00
TG Therapeutics Competitors 480 2263 6183 119 2.66

TG Therapeutics currently has a consensus target price of $26.75, indicating a potential upside of 236.48%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.29%. Given TG Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe TG Therapeutics is more favorable than its competitors.

Valuation & Earnings

This table compares TG Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
TG Therapeutics $152,381.00 -$104.96 million -4.08
TG Therapeutics Competitors $207.79 million -$2.30 million 0.43

TG Therapeutics’ competitors have higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

49.9% of TG Therapeutics shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 16.7% of TG Therapeutics shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

TG Therapeutics has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, TG Therapeutics’ competitors have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.


TG Therapeutics competitors beat TG Therapeutics on 7 of the 12 factors compared.

About TG Therapeutics

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with's FREE daily email newsletter.